Discover Petrichor and our portfolio companies

Petrichor and portfolio news

Scion Life Sciences news

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

August 2024

Read more on

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

July 2024

Read more on

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

July 2024

Read more on

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

June 2024

Read more on

ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth

June 2024

Read more on

Aurion Biotech Receives Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Its Drug Candidate AURN001

June 2024

Read more on

ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing

June 2024

Read more on

Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer

May 2024

Read more on

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

May 2024

Read more on

ITM Appoints Dr. Danielle Meyrick as Chief Medical Officer

May 2024

Read more on

Aurion Biotech Announces Completion of Enrollment in Phase 1/2 Clinical Trial

April 2024

Read more on

ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial

April 2024

Read more on

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

April 2024

Read more on

Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production

April 2024

Read more on

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

March 2024

Read more on

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

March 2024

Read more on

Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies

February 2024

Read more on

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

January 2024

Read more on

ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site

January 2024

Read more on

ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics

December 2023

Read more on

Fennec announces incremental $5 million investment from Petrichor

December 2023

Read more on

Aurion Biotech Announces First Subject Dosed in U.S. Phase 1 / 2 Clinical Trial

October 2023

Read more on

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

October 2023

Read more on

ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

October 2023

Read more on

Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED)

August 2023

Read more on

ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer

June 2023

Read more on

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

June 2023

Read more on

ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities

June 2023

Read more on

Gene & cell therapy manufacturing specialist Ascend launches with over $130M of funding as expert teams merge

May 2023

Read more on

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

March 2023

Read more on

Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

March 2023

Read more on

ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

March 2023

Read more on

Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved The

March 2023

Read more on

VERO Biotech's Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite

February 2023

Read more on

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

January 2023

Read more on

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

January 2023

Read more on

VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System

January 2023

VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System

January 2023

Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases

January 2023

Aurion Biotech Wins Prestigious Prix Galien Startup Award

October 2022

Read more on

ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

October 2022

Read more on ITM

Aurion Biotech Wins Prestigious Prix Galien Startup Award

October 2022

Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

October 2022

Read more on Fennec Pharmaceuticals

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

September 2022

Read more on Fennec Pharmaceuticals

Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

September 2022

Read more on Fennec Pharmaceuticals

Petrichor's Tadd Wessel discusses the state of healthcare investing with Elana Margulies Snyderman and EisnerAmper

August 2022

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

August 2022

Read more on Fennec Pharmaceuticals

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

May 2022

Petrichor Managing Partner Tadd Wessel Joins the ICPO Foundation Board of Curators

May 2022

Aurion Biotech Raises $120 Million from Deerfield Management, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures

April 2022

ITM Announces Successful Completion of Patient Recruitment for its Phase III Trial, COMPETE, with Lead Radiotherapeutic ITM-11 (n.c.a. lutetium-177-edotreotide)

April 2022

Read more on ITM

ITM Provides n.c.a. Lutetium-177 as Long-Term Supplier for Recently Approved Novel Radiotherapeutic in Metastatic Prostate Cancer

March 2022

Read more on ITM

LumiraDx to Become Publicly Traded following Successful Closing of Merger with CA Healthcare Acquisition Corp.

September 2021

Leukocare Announces USD 17.5 Million Financing Round to Further Expand US Business and Bioinformatics Activities

June 2021

ITM raises EUR 90 M (USD 109 M) to accelerate precision oncology pipeline and support ongoing phase 3 clinical program

April 2021

Read more on ITM

Petrichor Closes Oversubscribed Fund I at $410 Million

November 2020

Blackstone invests $275 million in Cryoport to fund acquisition of MVE Biological Solutions

October 2020

MRI Interventions, Inc. Obtains a $17.5 Million Strategic Investment from PTC Therapeutics, Inc. and Petrichor Healthcare Capital Management

January 2020

Persivia Secures $15 Million Growth Financing from Petrichor Healthcare Capital Management

October 2019

Cryoport Announces $25 Million Investment from Petrichor Healthcare Capital Management

December 2018